PREVENT and DCP-funded Early Phase Clinical Projects’ Results Presented at AACR Virtual Annual Meetings 2020 I & II

Date Posted: 

Wednesday, April 29, 2020

Updated: July 9, 2020

NCI participated in the American Association for Cancer Research (AACR) Annual Meetings, held virtually on April 27 - 28, 2020 (Meeting I) and June 22 - 24, 2020 (Meeting II), including presenting the following research results from PREVENT and Early Phase Clinical Projects outlined below.

The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a peer-reviewed program designed to support development of the best ideas in cancer prevention using National Cancer Institute contract resources. The program is a pipeline that focuses on unmet needs in prevention that are not adequately addressed by the private sector. NCI actively partners with successful applicants to help them move their novel cancer preventive chemical or biological agents (singly or in combination) and biomarkers from the lab bench towards IND filing, proof-of principle clinical testing and registration or validation.

The Division of Cancer Prevention conducts systematic early clinical development of promising preventive agents through its Phase 0/I/II Cancer Prevention Clinical Trials Program, also known as the Consortia for Early Phase Prevention Trials. Cancer prevention drug discovery is identifying many new agents, including an increasing number of agents that intervene in specific molecular pathways thought to be critical to cancer development. Since cancer prevention studies focus on high-risk populations that do not necessarily harbor a detectable cancer, these studies require extensive biomarker analysis, investigation of the biologic effects of the cancer preventive agents on their intended molecular targets, and correlation with clinically relevant endpoints.

PREVENT-funded Project Presentations

Tuesday, April 28
10:45 a.m. — 12:30 p.m.

Session Type: Virtual Minisymposium
Session Category: Prevention Research
Session Title: Prevention Research
Location: Virtual

1099—Combination of bazedoxifene and lapatinib profoundly inhibits estrogen receptor positive (ER+) and Negative (ER-) mammary tumorigenesis
Altaf Mohammed1, Shizuko Sei1, Robert H. Shoemaker1, Clinton J. Grubbs2. 1National Cancer Institute, Rockville, MD; 2Univ. of Alabama Comp. Cancer Ctr., Birmingham, AL.

1102—Model optimization and chemoprevention of IPMN driven PDAC in KPSD4 mouse model
Gaurav Kumar1, Venkateshwar Madka1, Anil Singh1, Nandini Kumar1, Nicole Stratton1, Stanley Lightfoot1, Altaf Mohammed2, Mark S. Miller2, Chinthalapally V. Rao1. 1Univ. of Oklahoma Health Sciences Ctr., Oklahoma City, OK; 2National Cancer Institute, Rockville, MD.

DCP-funded Early Phase Clinical Project Presentations

Monday, April 27
9:00 a.m. — 6:00 p.m.

Session Type: Virtual Poster Session
Session Category: Clinical Trials
Session Title: Phase I Clinical Trials
Location: Virtual

CT111—Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Laura Ryes Uribe1, Wenhui Wu1, Ozkan Gelincik2, Prashant V. Bommi1, Alejandro Francisco-Cruz1, Luisa M. Solis1, Patrick M. Lynch1, Romana Lim3, Elena Stoffel4, Priyanka Kanth5, N. Jewel Samadder6, Maureen E. Mork1, Melissa W. Taggart1, Ginger L. Milne7, Lawrence J. Marnett7, Lana Vornik1, Diane D. Liu1, Maria Revuelta2, Kyle Chang1, Y. Nancy You1, Levy Kopelovich2, Ignacio I. Wistuba1, J. Jack Lee1, Shizuko Sei8, Robert H. Shoemaker8, Eva Szabo8, Ellen Richmond8, Asad Umar8, Marjorie Perloff8, Powell H. Brown1, Steven M. Lipkin2, Eduardo Vilar1. 1The University of Texas MD Anderson Cancer Center, Houston TX; 2Weill Cornell Medical College, New York, NY; 3Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA; 4University of Michigan, Ann Arbor, MI; 5Huntsman Cancer Institute, Salt Lake City, UT; 6Mayo Clinic, Phoenix, AZ; 7Vanderbilt University School of Medicine, Nashville, TN; 8NCI Division of Cancer Prevention, Bethesda, MD.

PREVENT-funded Poster Presentations

Virtual Meeting II E-Posters

Session: PO.MCB10.03
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Non-coding RNAs in Cancer 3

2540 - Chemoprevention of aerosolized Let-7b in mouse lung cancer model
Qi Zhang1, Jing Pan1, Yian Wang1, Mark S. Miller2, Alberto Izzotti3, Ming You1. 1Medical College of Wisconsin, Milwaukee, WI, 2National Cancer Institute, Bethesda, MD, 3University of Genoa, Genoa, Italy

Session: PO.IM02.22
Session Category: Immunology
Session Title: Vaccines

4584 - A novel combination of a multipeptide KRAS vaccine and an ACAT1 inhibitor to prevent lung cancer
Jing Pan1, Qi Zhang1, Katie Palen1, Bryon Johnson1, Li Wang2, Shizuko Sei3, Robert H. Shoemaker3, Ronald A. Lubet3, Yian Wang1, Ming You1. 1Medical College of Wisconsin, Milwaukee, WI, 2Lerner Research Institute, Cleveland, OH, 3National Cancer Institute, Bethesda, MD

4563 - Immunoprevention of triple negative breast cancer by a multi-antigen, multi-peptide vaccine
Sang Beom Lee1, Jing Pan1, Yueqiang Jiang1, Katie Palen1, Bryon Johnson1, Romaine Ingrid Fernando2, Shizuko Sei2, Ronald Lubet2, Ming You1, and Yian Wang1. 1Medical College of Wisconsin, Milwaukee, WI, 2National Cancer Institute, Bethesda, MD, USA

Session: PO.PR01.01
Session Category: Prevention Research
Session Title: Preclinical Prevention Studies

13 - Aspirin and metformin combination inhibits PDAC progression and metastasis in KPC mice
Altaf Mohammed1, Venkateshwar Madka2, Gaurav Kumar2, Anil Singh2, Nicole Stratton2, Stanley Lightfoot2, Mark S. Miller1, Chinthalapally V. Rao2. 1National Cancer Institute, Rockville, MD, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK.

14 - TRAIL inducing small molecule ONC201 prevents intestinal tumors in FAP mouse model
Chinthalapally V. Rao1, Venkateshwar Madka1, Yuting Zhang1, Gopal Pathuri1, Janani Panneerselvam1, Nicole Stratton1, Niklas K. Finnberg2, Howard P. Safran3, Jennifer Fox4, Shizuko Sei4, Elizabeth R. Glaze4, Robert Shoemaker4, Wafik S. El-Deiry3,5. 1University of Oklahoma Health Sciences Center, 2Fox Chase Cancer Center, Philadelphia, PA, 3Lifespan Cancer Institute (LCI), Providence, RI, 4National Cancer Institute, Rockville, MD, 5Brown University, Providence, RI

15 - Hypertension drug Olmesartan medoxomil promotes colonic tumorigenesis in AOM-induced CRC rat model
Venkateshwar Madka1, Yuting Zhang1, Gopal Pathuri1, Janani Panneerselvam1, Nicole Stratton1, Anil Singh1, Shizuko Sei2, Jennifer Fox2, Chinthalapally V. Rao1. 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2National Cancer Institute, Rockville, MD

v19 - Examination of HJC0152, a putative modulator of glucose and energy metabolism, for mammary cancer prevention
Hyejin Kim1, Xi Liu1, Yefei Wen1, Jia Zhou2, Romaine Fernando3, Shizuko Sei3, Powel H. Brown1, Qiang Shen1. 1The University of Texas MD Anderson Cancer Center, Houston, TX, 2University of Texas Medical Branch, Galveston, TX, 3National Cancer Institute, Rockville, MD

21 - Optimization of dosing regimens of sulindac in combination with erlotinib for small intestine and colorectal cancer prevention
Praveen Rajendran1, Ahmetmursel Ulusan1, Wan-Mohaiza Dashwood1, Sabeeta Kapoor1, Altaf Mohammed2, Shizuko Sei2, Asif Rashid3, Powel H. Brown3, Eduardo Vilar-Sanchez3, Roderick H. Dashwood1. 1Texas A&M Health Science Center-IBT, Houston, TX, 2National Cancer Institute, Rockville, MD, 3University of Texas MD Anderson Cancer Center, Houston, TX

27 - Development of a rat model of atypical endometrial hyperplasia and a vaginal suppository formulation of SHetA2 for chemoprevention studies
Vishal Chandra, Rajani Rai, Sanam Hussain, Lucila Garcia, Manolya Hatipoglu, Doris Benbrook. University of Oklahoma Health Sciences Center, Oklahoma City, OK

Session: PO.ET06.10
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 3

6364 - LFA-9, a dual mPGES-1 and 5-LOX inhibitor, suppresses colon cancer stemness and inflammogen-induced inflammatory response
Nagendra Sastri Yarla1, Gopal Pathuri1, Hariprasad Gali1, Venkateshwar Madka1, Janani Panneerselvam1, Parthasarathy Chandrakesan1, Courtney W. Houchen1, Elizabeth R. Glaze2, Jennifer Fox2, David McCormick3, Chinthalapally V. Rao1. 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2National Cancer Institute, Rockville, MD, 3IIT Research Institute, Chicago, IL

Session MW04 - Clinical Trial Design: Part 4: Trial Design for Early Cancer Detection

Wednesday, June 24
4:00 p.m. — 6:00 p.m.

Session Type: Methods Workshop
Session Category: Clinical Trials
Session Title: Clinical Trial Design: Part 4: Trial Design

June 24, 2020, 4:00 p.m. — 4:20 p.m. 
Biomarkers for early-phase cancer prevention/immunoprevention trials
Asad Umar. NCI-DCP, Rockville, MD

June 24, 2020, 4:30 p.m. — 4:50 p.m.
Exploring tissue biomarker variability and effect on early-phase clinical trials in cancer prevention
Howard H. Bailey. University of Wisconsin Carbone Comp. Cancer Center, Madison, WI

June 24, 2020, 5:30 p.m. — 5:50 p.m.
Cancer prevention/immunoprevention strategies for high-risk cancers (Lynch syndrome)
Eduardo Vilar-Sanchez. University of Texas MD Anderson Cancer Center, Houston, TX